as 10-28-2024 4:00pm EST
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Upcoming Earnings Alert:
Get ready for potential market movements as AlloVir Inc. ALVR prepares to release earnings report on 04 Nov 2024.
Founded: | 2013 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 87.7M | IPO Year: | 2020 |
Target Price: | $1.00 | AVG Volume (30 days): | 134.7K |
Analyst Decision: | Sell | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.23 | EPS Growth: | N/A |
52 Week Low/High: | $0.58 - $2.48 | Next Earning Date: | 11-04-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Miller Edward | ALVR | General Counsel | Oct 21 '24 | Sell | $0.77 | 1,401 | $1,082.80 | 214,203 | |
Sinha Vikas | ALVR | See Remarks | Oct 21 '24 | Sell | $0.77 | 3,428 | $2,649.33 | 1,149,216 | |
Brainard Diana | ALVR | Chief Executive Officer | Oct 21 '24 | Sell | $0.78 | 9,752 | $7,596.81 | 742,678 | |
Miller Edward | ALVR | General Counsel | Oct 3 '24 | Sell | $0.81 | 377 | $307.18 | 214,203 | |
Sinha Vikas | ALVR | See Remarks | Oct 3 '24 | Sell | $0.81 | 940 | $765.91 | 1,149,216 | |
Brainard Diana | ALVR | Chief Executive Officer | Oct 3 '24 | Sell | $0.81 | 1,493 | $1,216.50 | 742,678 | |
Brainard Diana | ALVR | Chief Executive Officer | Aug 20 '24 | Sell | $0.74 | 5,390 | $3,995.61 | 742,678 | |
Miller Edward | ALVR | General Counsel | Aug 19 '24 | Sell | $0.76 | 422 | $320.51 | 214,203 | |
Sinha Vikas | ALVR | See Remarks | Aug 19 '24 | Sell | $0.76 | 3,159 | $2,399.26 | 1,149,216 | |
Hagen Brett R | ALVR | Chief Accounting Officer | Aug 19 '24 | Sell | $0.76 | 544 | $413.17 | 71,981 |
ALVR Breaking Stock News: Dive into ALVR Ticker-Specific Updates for Smart Investing
GuruFocus.com
18 days ago
Simply Wall St.
3 months ago
GlobeNewswire
5 months ago
PR Newswire
5 months ago
Business Wire
5 months ago
Business Wire
5 months ago
Reuters
5 months ago
Investor's Business Daily
5 months ago
The information presented on this page, "ALVR AlloVir Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.